FMS-like tyrosine kinase 3 (FLT3) mutations occur in almost 30% of acute myeloid leukemia
(AML) patients. Despite the initial clinical efficacy of FLT3 inhibitors, many treated AML …

Breast cancer (BC) still poses a threat worldwide which demands continuous efforts to
present safer and efficacious treatment options via targeted therapy. Beside kinases' …

Alternative splicing (AS) is an efficient and ubiquitous transcriptional regulatory mechanism
that expands the coding capacity of the genome and is associated with the occurrence and …

Here, we discover an FLT3/CHK1 dual inhibitor (30) that exhibits excellent kinase potency
and antiproliferative activity against MV4-11 cells. Simultaneously, 30 possesses high …

Malignant transformation of healthy cells into cancer is a process that develops over time.
Since the discovery of the human genome, great advances have been made in cancer …